Vir Biotechnology is advancing in its ECLIPSE Phase 3 program, a pivotal moment in chronic hepatitis delta (CHD) treatment. Combination therapy with tobevibart and elebsiran
Vir Biotechnology is advancing in its ECLIPSE Phase 3 program, a pivotal moment in chronic hepatitis delta (CHD) treatment. Combination therapy with tobevibart and elebsiran